Matthias Goebeler
Chair
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (14)
Immune-checkpoint inhibitors (ICIs) benefit patients with advanced melanoma, yet resistance remains common and the myeloid circuits that limit response are incompletely defined. We identify glucocorticoid receptor (GR) signaling in tumor-associated macrophages (TAMs) as a druggable brake on antitumor immunity under PD 1 blockade. Myeloid-specific GR deletion restored immune recognition and overcame anti-PD 1 resistance, resulting in restrained melanoma growth. CITE-seq revealed that GR loss reprogrammed multiple TAM subsets towards interferon-licensed, antigen-presenting, chemokine-producing states, reshaping T cell composition toward cytotoxic effector and tissue-resident memory phenotypes with attenuated exhaustion. Cross-species analyses linked glucocorticoid activity and GR-regulated myeloid and T cell states to clinical response. To therapeutically exploit this axis, we engineered CD169-targeted lipid nanoparticles delivering the GR antagonist mifepristone to TAMs. Targeted GR antagonism re-educated the immune niche, restored T cell stimulatory capacity, and synergized with PD 1 blockade in ICI-refractory melanoma. These data nominate myeloid GR inhibition as a biomarker-guided strategy to enhance ICI efficacy.
Year:
2025
Zusammenfassung Hintergrund Kutane periphere T‐Zell‐Lymphome (PTCL) sind selten und zeigen einen aggressiven Verlauf mit limitiertem Therapieansprechen. Die Wirksamkeit von Brentuximab‐Vedotin bei kutanen PTCL wurde bisher nicht systematisch untersucht. Patienten und Methodik In dieser retrospektiven Datenanalyse evaluierten wir die Therapie mit Brentuximab‐Vedotin als Mono‐ oder Kombinationstherapie bei kutanen CD30‐positiven PTCL (n = 9). Ergebnisse Insgesamt zeigten sich gutes Ansprechen und akzeptable Verträglichkeit der Therapie. Ein Patient erzielte eine nahezu komplette Remission, bei fünf Patienten wurde eine partielle Remission und bei zwei Patienten ein gemischtes Ansprechen als bestes Ansprechen ( best overall response , BOR) beobachtet. Im Median vergingen 31,5 Tage (Interquartilabstand 12–53) bis zum Therapieansprechen. Die mediane Ansprechdauer war mit 4,3 Monaten kurz; das mediane Gesamtüberleben seit Einleitung der Brentuximab‐Vedotin‐Therapie betrug 15,2 Monate. Vier von neun Patienten verstarben an ihrer fortgeschrittenen Lymphomerkrankung, ein Patient verstarb aus anderer Ursache. Schlussfolgerungen Brentuximab‐Vedotin als Mono‐ oder Kombinationstherapie ist bei Patienten mit kutanem peripheren T‐Zell‐Lymphom eine rasch wirksame und verträgliche Therapieoption bei allerdings nur kurzer Ansprechdauer.
Year:
2025
Background and Objectives While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30‐positive cutaneous T‐cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce. In this retrospective analysis, we evaluated the combination of BV and RTx in patients with CD30‐positive CTCL. Patients and Methods We included 14 CD30‐positive CTCL patients from six German cancer centers receiving BV; RTx was initiated within a timeframe of 3 months prior/after BV treatment. RTx was mainly applied as a low‐dose scheme. Results Adverse events of any grade occurred in 71% of patients, most commonly peripheral neuropathy, neutropenia, and radiodermatitis. Thirteen patients achieved a complete or partial remission as best overall response, however, 50% of all patients showed disease progression. At a median follow‐up of 14.4 months, median progression‐free survival was 12.0 months, with a 1‐year rate of 34.0%. Conclusions The simultaneous or sequential use of RTx during BV treatment was feasible and well tolerated. Future randomized investigations are needed to identify the benefits of this combination treatment regimen as well as adequate dosing of BV and RTx in a prospective manner.
Year:
2025
Background Cutaneous peripheral T cell lymphomas (PTCL) are rare and show an aggressive course with limited response to therapy. The efficacy of brentuximab vedotin in cutaneous peripheral T cell lymphomas has not yet been systematically investigated. Patients and methods In this retrospective analysis, we evaluated brentuximab vedotin as monotherapy or in combination therapy in patients with cutaneous CD30‐positive peripheral T cell lymphoma (n = 9). Results Overall, the therapy showed good efficacy and acceptable tolerability. One patient achieved an almost complete response, five had a partial response, and two had a mixed response as best overall response. The median time to response was 31.5 days (interquartile range 12–53). The median duration of response was short at 4.3 months. Median overall survival from initiation of brentuximab vedotin was 15.2 months; four of nine patients died from advanced lymphoma and one patient died from an unrelated cause. Conclusion Brentuximab vedotin as monotherapy or combination therapy is a rapidly effective and tolerable treatment option for patients with cutaneous PTCL, although the duration of response is short.
Year:
2025
Zusammenfassung Die immunsuppressive und ‐modulierende Behandlung dermatologischer Patienten macht eine Überprüfung und gegebenenfalls Aktualisierung notwendiger Standard‐ und Indikationsimpfungen erforderlich. Die Ständige Impfkommission (STIKO) am Robert Koch‐Institut veröffentlicht regelmäßig evidenzbasierte Impfempfehlungen, die an die aktuelle epidemiologische Situation und Verfügbarkeit von Impfstoffen angepasst werden. Seit 2020 ergaben sich mehrere Neuerungen, die auch für Patienten mit dermato(onko)logischen Erkrankungen relevant sind: (1) Mit COVID‐19 wurde eine neue virale Erkrankung definiert und mehrere Impfstoffe zu deren Prävention eingeführt; (2) in Reaktion auf den weltweiten Mpox‐Ausbruch 2022 erhielt ein 2013 zur Prävention der Pocken zugelassener, auf dem modifizierten Vacciniavirus Ankara basierender, nicht vermehrungsfähiger Lebendimpfstoff eine Indikationserweiterung; (3) für die Influenza‐Schutzimpfung von Personen ≥ 60 Jahren wurde ein neuer inaktivierter Hochdosisimpfstoff zugelassen; (4) für die Pneumokokkenschutzimpfung steht ein neuer 20‐valenter Konjugatimpfstoff zur Verfügung; (5) zuletzt neu zugelassen wurden zwei rekombinante Impfstoffe gegen das respiratorische Synzytial‐Virus (RSV). Die vorliegende Arbeit erörtert die entsprechend angepassten STIKO‐Empfehlungen für Erwachsene mit besonderer Würdigung ihrer Umsetzung bei immunkompromittierten Patienten in der Dermatologie.
Year:
2025
Background Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by painful nodules, abscesses, and fistulas in intertriginous sites. It significantly impacts patients’ quality of life. Early diagnosis and timely treatment are essential for disease control. Recurrent flares, suboptimal therapies, and prolonged misdiagnosis place a significant burden on both patients and health care systems. Objective We aimed to identify mobile health apps (MHAs) for patients with HS and evaluate their quality through assessments by both patients and physicians. Methods Two reviewers searched for mobile and web apps for HS, including those only available in German or English. Apps with advertising or non–patient-centered content and apps related to trials or conferences were excluded. Two apps met the criteria and were evaluated by 20 physicians and 27 patients using the Mobile App Rating Scale (MARS), user version of the MARS (uMARS), German Mobile App Usability Questionnaire, and technology affinity tools (Affinity for Technology Interaction Scale and Mobile Device Proficiency Questionnaire). Results We identified 2 apps for managing HS that met the inclusion criteria—the HSR-Patients app and the EHSF-Hidradenitis Suppurativa app—from an initial pool of 29 proposed apps that included many nonmedical, non–HS-specific, and non–patient-centered apps. Patients rated the quality of the HSR-Patients app significantly higher than physicians (MARS: mean 3.01, SD 0.60 vs. uMARS: mean 3.53, SD 0.69; P =.009). In contrast, ratings for the EHSF-Hidradenitis Suppurativa app did not differ significantly (physicians: mean 2.81, SD 0.55; patients: mean 2.72, SD 0.79; P =.69). Usability, assessed with the German Mobile App Usability Questionnaire, showed no significant difference between physicians and patients for either app. For the HSR-Patients app, physicians and patients rated usability at 4.37 (SD 0.86) and 4.72 (SD 1.21; P =.27), respectively. For the EHSF-Hidradenitis Suppurativa app, physicians and patients rated usability at 3.88 (SD 0.77) and 3.38 (SD 1.35; P =.11), respectively. Patients showed a significantly higher general affinity for technology than physicians, as measured by the Affinity for Technology Interaction Scale (physicians: mean 3.62, SD 0.61; patients: mean 4.38, SD 1.30; P =.01). However, there was no significant difference in affinity for technology specifically when using mobile devices, as assessed by the Mobile Device Proficiency Questionnaire (physicians: mean 4.83, SD 0.25; patients: mean 4.69, SD 0.72; P =.41). Conclusion s This evaluation highlights the limited availability of high-quality, HS management–specific MHAs and underscores the need for more targeted digital tools. Differences in evaluations between patients and physicians were evident, with patients focusing on usability and practical guidance, while physicians prioritized content and usability. Neither the HSR-Patients app or the EHSF-Hidradenitis Suppurativa app demonstrated sufficient potential for long-term use, indicating the need for participatory development that includes all stakeholders.
Year:
2025
The immunosuppressive and immunomodulatory treatment of dermatological patients necessitates the regular review and updating of standard vaccinations and vaccines indicated for specific conditions. The German Standing Committee on Vaccination (STIKO) at the Robert Koch Institute regularly publishes evidence‐based vaccination recommendations, which are adapted to the current epidemiological situation and availability of vaccines. Since 2020, several changes have been made that are relevant for patients with dermato(onco)logical diseases: (1) COVID‐19 was defined as a new viral disease and several vaccines have been introduced; (2) in response to the global Mpox outbreak in 2022, a non‐replicating live vaccine based on the modified Ankara vaccinia virus, which was approved in 2013 for the prevention of smallpox, was given an indication extension; (3) a new inactivated high‐dose vaccine was approved for influenza vaccination of persons aged 60 years and older; (4) a new 20‐valent conjugate vaccine is available for pneumococcal vaccination; (5) two recombinant vaccines against the respiratory syncytial virus (RSV) were recently approved. This article discusses the correspondingly adapted STIKO recommendations for adults, with particular emphasis on their implementation in immunocompromised patients in dermatology.
Year:
2025
Activation of the JAK/STAT signalling pathway plays a pivotal role in the pathogenesis of cutaneous T-cell lymphomas. Therefore, inhibition of this cardinal pathway is a promising novel treatment option. Here, we report the first evidence of rapid response of lymphomatoid papulosis and mycosis fungoides upon topical application of the Janus kinase inhibitor ruxolitinib.
Year:
2025
Digital papillary adenocarcinoma (DPAC) is a rare, low-grade sweat gland carcinoma primarily found on the hands, fingers, or toes and predominantly affecting males. Distinguishing DPAC from benign sweat gland tumors can be challenging. We present the case of a 52-year-old patient with a progressive tumor on the finger initially misdiagnosed as a viral wart. Histological examination revealed a cytologically basophilic sweat gland tumor with tubular structures, papillary protrusions, and a characteristic immunohistochemical staining pattern for CK 7 and Actin. HPV-42 positivity and molecular analysis confirmed the diagnosis of DPAC. HPV-42 has been strongly associated with DPAC. Additionally, p16 positivity and BRAFV600E negativity were observed. These findings aid in the differential diagnosis of acral sweat gland tumors and guide clinical management, including with respect to the potential for recurrence and metastasis.
Year:
2024
Background Early detection of melanoma, a potentially lethal type of skin cancer with high prevalence worldwide, improves patient prognosis. In retrospective studies, artificial intelligence (AI) has proven to be helpful for enhancing melanoma detection. However, there are few prospective studies confirming these promising results. Existing studies are limited by low sample sizes, too homogenous datasets, or lack of inclusion of rare melanoma subtypes, preventing a fair and thorough evaluation of AI and its generalizability, a crucial aspect for its application in the clinical setting. Methods Therefore, we assessed “All Data are Ext” (ADAE), an established open-source ensemble algorithm for detecting melanomas, by comparing its diagnostic accuracy to that of dermatologists on a prospectively collected, external, heterogeneous test set comprising eight distinct hospitals, four different camera setups, rare melanoma subtypes, and special anatomical sites. We advanced the algorithm with real test-time augmentation (R-TTA, i.e., providing real photographs of lesions taken from multiple angles and averaging the predictions), and evaluated its generalization capabilities. Results Overall, the AI shows higher balanced accuracy than dermatologists (0.798, 95% confidence interval (CI) 0.779–0.814 vs. 0.781, 95% CI 0.760–0.802; p = 4.0e−145), obtaining a higher sensitivity (0.921, 95% CI 0.900–0.942 vs. 0.734, 95% CI 0.701–0.770; p = 3.3e−165) at the cost of a lower specificity (0.673, 95% CI 0.641–0.702 vs. 0.828, 95% CI 0.804–0.852; p = 3.3e−165). Conclusion As the algorithm exhibits a significant performance advantage on our heterogeneous dataset exclusively comprising melanoma-suspicious lesions, AI may offer the potential to support dermatologists, particularly in diagnosing challenging cases.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (13)
Angela Riedel
Junior Group Leader
University of Würzburg
Anders Etzerodt
VIP, Associate Professor
Aarhus University
Leo Rasche
University Hospital Würzburg
Bastian Schilling
Director and Chair
Goethe University Frankfurt
Titus Josef Brinker
Clinician Scientist / Head of App Development
University Hospital Heidelberg
Viktor Umansky
Heidelberg University
Lars French
Professor of Precision and Translational Dermatology
Ludwig-Maximilians-Universität München
Markus V Heppt
Universitätsklinikum Erlangen
Antoine-Emmanuel Saliba
Prof
Helmholtz Institute for RNA-based Infection Research
Andreas Kerstan
Assistant professor
Universitätsklinikum Würzburg
Dirk Schadendorf
University Hospital Essen
Kamran Ghoreschi
Director/Prof.Dr
Charité - Universitätsmedizin Berlin
Wiebke Sondermann
Deputy Director
University Hospital Erlangen
Make your next move.
Prepare your application
Review drafts before you send them.